Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

4 reports from 4 outlets in 1 language · first reported 2026-09-30 12:05 UTC · updated 2026-10-02 12:00 UTC · JSON

Reports

1. Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026Published by manilatimes.net, GlobeNewswire — all · 2026-09-30 12:19 UTC
2. Aglatimagene Besadenovec Shows Durable Immune Activity in Intermediate-Risk Localized Prostate Canceronclive.com · en · 2026-10-02 12:00 UTC
3. Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate CancerGlobeNewswire — public companies · en · 2026-09-30 12:30 UTC